ITF3912
/ Italfarmaco
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Targeted DNA damage through SSTR2: Preclinical development of a novel peptide-drug conjugate for neuroendocrine tumors
(AACR 2026)
- "These results support the use of ITF3912 as a therapeutic option for patients with SSTR2-positive neuroendocrine tumors, addressing a significant unmet medical need. Encouraging preliminary toxicology results, further support the progression of ITF3912 toward clinical development."
Preclinical • Endocrine Cancer • Gastrointestinal Neuroendocrine Tumor • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • CHEK1 • CHEK2 • CTSC • RPA2 • SSTR • SSTR2
1 to 1
Of
1
Go to page
1